Trial Outcomes & Findings for A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. (NCT NCT02711345)
NCT ID: NCT02711345
Last Updated: 2019-09-19
Results Overview
An adverse events is defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occur after participant's signed informed consent has been obtained. A SAE is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
65 participants
Primary outcome timeframe
Up to 2.8 years
Results posted on
2019-09-19
Participant Flow
Participant milestones
| Measure |
LTT462 45 mg QD
Participants received LTT462 45 milligram (mg) once daily (QD)
|
LTT462 100 mg QD
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
Participants received 150 mg LTT462 twice daily (BID) as oral capsules.
|
LTT462 200 mg BID
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
2
|
3
|
6
|
4
|
8
|
6
|
12
|
6
|
6
|
12
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
2
|
3
|
6
|
4
|
8
|
6
|
12
|
6
|
6
|
12
|
Reasons for withdrawal
| Measure |
LTT462 45 mg QD
Participants received LTT462 45 milligram (mg) once daily (QD)
|
LTT462 100 mg QD
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
Participants received 150 mg LTT462 twice daily (BID) as oral capsules.
|
LTT462 200 mg BID
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
0
|
0
|
2
|
|
Overall Study
Physician Decision
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Progressive disease
|
1
|
3
|
5
|
3
|
7
|
2
|
8
|
4
|
5
|
6
|
|
Overall Study
Subject/guardian decision
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
1
|
0
|
4
|
|
Overall Study
Death
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
Baseline Characteristics
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
Baseline characteristics by cohort
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 once QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
Total
n=65 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
44 Participants
n=42 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
20 Participants
n=42 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
7 Participants
n=42 Participants
|
40 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
25 Participants
n=42 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
42 Participants
n=42 Participants
|
|
Race/Ethnicity, Customized
Black
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
|
Race/Ethnicity, Customized
Asian
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
14 Participants
n=42 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
00 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: Up to 2.8 yearsPopulation: The safety set included all participants who had received at least one dose of LTT462.
An adverse events is defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occur after participant's signed informed consent has been obtained. A SAE is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs
|
2 Percentage of participants
|
3 Percentage of participants
|
6 Percentage of participants
|
4 Percentage of participants
|
8 Percentage of participants
|
6 Percentage of participants
|
12 Percentage of participants
|
5 Percentage of participants
|
6 Percentage of participants
|
12 Percentage of participants
|
|
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
SAEs
|
1 Percentage of participants
|
0 Percentage of participants
|
3 Percentage of participants
|
1 Percentage of participants
|
5 Percentage of participants
|
1 Percentage of participants
|
8 Percentage of participants
|
4 Percentage of participants
|
3 Percentage of participants
|
5 Percentage of participants
|
PRIMARY outcome
Timeframe: Up to 2.8 yearsPopulation: The dose determining set included all participants from the safety set enrolled in the escalation part of the study who, during the first 28 days of dosing, had received at least 75 percent of the planned daily doses of LTT462 and had had sufficient safety evaluations, or had experienced a DLT.
Percentage of participants with dose limiting toxicity were reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=7 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=4 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=7 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=3 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=4 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=9 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Dose Limiting Toxicities (DLTs)
|
0 Percentage of participants
|
0 Percentage of participants
|
16.7 Percentage of participants
|
25.0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
28.6 Percentage of participants
|
100 Percentage of participants
|
0 Percentage of participants
|
44.4 Percentage of participants
|
PRIMARY outcome
Timeframe: Up to 2.8 yearsPopulation: The safety set included all participants who had received at least one dose of LTT462.
Percentage of participants with at least one dose reduction were reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With at Least One Dose Reduction
|
0 Percentage of participants
|
0 Percentage of participants
|
16.7 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
16.7 Percentage of participants
|
33.3 Percentage of participants
|
16.7 Percentage of participants
|
33.3 Percentage of participants
|
PRIMARY outcome
Timeframe: Up to 2.8 yearsPopulation: The safety set included all participants who had received at least one dose of LTT462.
Percentage of participants with at least dose interruptions were reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With at Least One Dose Interruptions
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
PRIMARY outcome
Timeframe: Up to 2.8 yearsPopulation: The safety set included all participants who had received at least one dose of LTT462.
Dose intensity of LTT462 received by treatment group was reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Dose Intensity Received by Participants
|
65.3 milligram per day (mg/day)
Standard Deviation 28.74
|
98.1 milligram per day (mg/day)
Standard Deviation 3.21
|
133.9 milligram per day (mg/day)
Standard Deviation 21.84
|
200.0 milligram per day (mg/day)
Standard Deviation 0.00
|
272.7 milligram per day (mg/day)
Standard Deviation 30.90
|
326.7 milligram per day (mg/day)
Standard Deviation 81.54
|
409.2 milligram per day (mg/day)
Standard Deviation 64.88
|
468.2 milligram per day (mg/day)
Standard Deviation 171.48
|
131.6 milligram per day (mg/day)
Standard Deviation 22.08
|
178.0 milligram per day (mg/day)
Standard Deviation 35.32
|
SECONDARY outcome
Timeframe: Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)Population: The full analysis set included all participants who had received at least one dose of LTT462.
Percentage of participants with overall response rate were reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Overall Response Rate (ORR)
|
0 Percentage of participants
Interval 0.0 to 84.2
|
0 Percentage of participants
Interval 0.0 to 70.8
|
0 Percentage of participants
Interval 0.0 to 45.9
|
0 Percentage of participants
Interval 0.0 to 60.2
|
0 Percentage of participants
Interval 0.0 to 36.9
|
0 Percentage of participants
Interval 0.0 to 45.9
|
0 Percentage of participants
Interval 0.0 to 26.5
|
0 Percentage of participants
Interval 0.0 to 45.9
|
0 Percentage of participants
Interval 0.0 to 45.9
|
0 Percentage of participants
Interval 0.0 to 26.5
|
SECONDARY outcome
Timeframe: Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)Population: The full analysis set included all participants who had received at least one dose of LTT462.
Percentage of participants with disease control rate were reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Disease Control Rate (DCR)
|
50.0 Percentage of participants
Interval 1.3 to 98.7
|
0 Percentage of participants
Interval 0.0 to 70.8
|
0 Percentage of participants
Interval 0.0 to 45.9
|
0 Percentage of participants
Interval 0.0 to 60.2
|
37.5 Percentage of participants
Interval 8.5 to 75.5
|
16.7 Percentage of participants
Interval 0.4 to 64.1
|
8.3 Percentage of participants
Interval 0.2 to 38.5
|
16.7 Percentage of participants
Interval 0.4 to 64.1
|
16.7 Percentage of participants
Interval 0.4 to 64.1
|
0 Percentage of participants
Interval 0.0 to 26.5
|
SECONDARY outcome
Timeframe: Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)Population: As there were no participant achieving response (CR or PR) during escalation phase of the study (only stable disease was achieved). Therefore the evaluation of duration of response could not be performed.
DOR is defined as the time between the date of the first documented response (complete response \[CR\] or partial response \[PR\]) and the date of progression.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)Population: The full analysis set included all participants who had received at least one dose of LTT462.
Median time for progression free survival was reported.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Progression Free Survival (PFS)
|
5.3 months
Interval 1.3 to 9.2
|
1.6 months
Interval 0.9 to 1.7
|
1.7 months
Interval 1.2 to 2.0
|
1.9 months
Interval 1.7 to 1.9
|
1.8 months
Interval 1.2 to 5.1
|
2.1 months
Interval 0.8 to 3.2
|
0.9 months
Interval 0.8 to 1.6
|
1.4 months
Interval 0.7 to 4.0
|
1.5 months
Interval 1.2 to 3.7
|
1.6 months
Interval 0.8 to 1.7
|
SECONDARY outcome
Timeframe: Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)Population: Overall survival was not evaluated because the study ended before enrolling into the dose-expansion part.
Median time for overall survival, only for dose expansion phase was reported.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: day 1, day 15Population: Pharmacokinetic (PK) analysis set (PAS) included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'n' number analyzed signifies number of participants who were evaluable at each time point.
Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration expressed in mass x volume-1.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=11 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=4 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Maximum (Peak) Observed Plasma, Blood, Serum, or Other Body Fluid Drug Concentration (Cmax) After Single Dose Administration of LTT462
Day 1
|
61.3 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 55.9
|
134 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 38.8
|
218 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 230.9
|
494 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 126.8
|
717 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 127.4
|
1580 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 60.8
|
1420 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 83.5
|
1280 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 47.7
|
598 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 83.0
|
575 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 73.8
|
|
The Maximum (Peak) Observed Plasma, Blood, Serum, or Other Body Fluid Drug Concentration (Cmax) After Single Dose Administration of LTT462
Day 15
|
139 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 29.9
|
938 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 82.5
|
707 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 69.0
|
972 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 92.4
|
1330 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 131.9
|
2370 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 83.3
|
3470 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 49.7
|
1030 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 248.8
|
1390 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 58.5
|
1510 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 108.0
|
SECONDARY outcome
Timeframe: Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1Population: PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'N' number of participants analyzed signifies number of participants who were evaluable for this outcome measure.
AUClast is the area under the curve from time zero to the last measurable concentration sampling time calculated by mass \* time \*volume\^-1
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=7 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=10 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=3 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=5 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of LTT462
|
851 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 106.0
|
2260 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 30.0
|
3880 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 133.6
|
10400 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 95.4
|
12800 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 157.4
|
23300 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 55.5
|
23800 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 115.3
|
11800 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 64.2
|
9240 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 78.3
|
7630 hour*nanogram per milliliter (h*ng/mL)
Geometric Coefficient of Variation 98.8
|
SECONDARY outcome
Timeframe: day 1, day 15Population: PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'n' number analyzed signifies number of participants who were evaluable at each time point.
Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=11 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=4 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Time to Reach Maximum (Peak) Plasma, Blood, Serum, or Other Body Fluid Drug Concentration (Tmax) After Single Dose Administration of LTT462
Day 1
|
2.45 hour
Interval 0.967 to 3.93
|
1.98 hour
Interval 0.867 to 24.0
|
3.49 hour
Interval 2.0 to 24.3
|
5.48 hour
Interval 3.0 to 46.4
|
3.08 hour
Interval 2.08 to 48.8
|
3.04 hour
Interval 1.12 to 4.0
|
3.98 hour
Interval 2.42 to 7.77
|
3.95 hour
Interval 2.0 to 4.2
|
2.25 hour
Interval 2.0 to 49.8
|
3.03 hour
Interval 0.467 to 7.78
|
|
The Time to Reach Maximum (Peak) Plasma, Blood, Serum, or Other Body Fluid Drug Concentration (Tmax) After Single Dose Administration of LTT462
Day 15
|
5.93 hour
Interval 4.0 to 7.85
|
4.02 hour
Interval 1.0 to 4.83
|
4.05 hour
Interval 2.13 to 8.0
|
3.00 hour
Interval 2.17 to 3.02
|
2.59 hour
Interval 1.58 to 4.03
|
2.55 hour
Interval 1.87 to 3.15
|
2.98 hour
Interval 1.0 to 7.62
|
5.25 hour
Interval 3.0 to 7.5
|
2.17 hour
Interval 2.05 to 3.15
|
2.18 hour
Interval 2.0 to 4.15
|
SECONDARY outcome
Timeframe: Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1Population: PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'N' number of participants analyzed signifies number of participants who were evaluable for this outcome measure.
T1/2 is the Elimination half-life.
Outcome measures
| Measure |
LTT462 45 mg QD
n=1 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=2 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=4 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=2 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=3 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=7 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=2 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=2 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=9 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Elimination Half-life (T1/2) of LTT462
|
27.9 hour
Interval 27.9 to 27.9
|
39.2 hour
Interval 28.8 to 49.5
|
20.8 hour
Interval 13.4 to 24.5
|
16.8 hour
Interval 16.7 to 16.8
|
15.2 hour
Interval 14.9 to 19.6
|
14.0 hour
Interval 12.0 to 18.7
|
17.6 hour
Interval 16.1 to 18.9
|
13.2 hour
Interval 11.8 to 14.5
|
16.2 hour
Interval 13.3 to 19.1
|
17.1 hour
Interval 11.6 to 41.1
|
SECONDARY outcome
Timeframe: Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1Population: PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'N' number of participants analyzed signifies number of participants who were evaluable for this outcome measure.
AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state calculated by formula amount \*time \* volume\^-1
Outcome measures
| Measure |
LTT462 45 mg QD
n=1 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=1 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=4 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=3 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=5 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=4 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=4 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=1 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=5 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=4 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Area Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of LTT462
|
3010 h*ng/mL
Geometric Coefficient of Variation NA
Geometric coefficient of variation was not calculated due to single participant in the arm.
|
6370 h*ng/mL
Geometric Coefficient of Variation NA
Geometric coefficient of variation was not calculated due to single participant in the arm.
|
8660 h*ng/mL
Geometric Coefficient of Variation 50.0
|
14600 h*ng/mL
Geometric Coefficient of Variation 96.5
|
13100 h*ng/mL
Geometric Coefficient of Variation 81.6
|
25400 h*ng/mL
Geometric Coefficient of Variation 74.3
|
35400 h*ng/mL
Geometric Coefficient of Variation 94.8
|
6760 h*ng/mL
Geometric Coefficient of Variation NA
Geometric coefficient of variation was not calculated due to single participant in the arm.
|
11100 h*ng/mL
Geometric Coefficient of Variation 59.5
|
18600 h*ng/mL
Geometric Coefficient of Variation 85.2
|
SECONDARY outcome
Timeframe: Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1Population: PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'N' number of participants analyzed signifies number of participants who were evaluable for this outcome measure.
Racc is the accumulation ratio calculated by AUCtau ratio Day 15 versus Day 1.
Outcome measures
| Measure |
LTT462 45 mg QD
n=1 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=1 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=4 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=3 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=4 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=4 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=3 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=4 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=4 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Accumulation Ratio (Racc) of LTT462
|
3.01 Ratio
Geometric Coefficient of Variation NA
Geometric coefficient of variation was not calculated due to single participant in the arm.
|
3.35 Ratio
Geometric Coefficient of Variation NA
Geometric coefficient of variation was not calculated due to single participant in the arm.
|
5.09 Ratio
Geometric Coefficient of Variation 72.7
|
2.74 Ratio
Geometric Coefficient of Variation 46.9
|
1.49 Ratio
Geometric Coefficient of Variation 25.1
|
1.73 Ratio
Geometric Coefficient of Variation 62.4
|
1.44 Ratio
Geometric Coefficient of Variation 73.4
|
—
|
3.19 Ratio
Geometric Coefficient of Variation 50.2
|
6.89 Ratio
Geometric Coefficient of Variation 84.3
|
SECONDARY outcome
Timeframe: Cycle 1 Days 1, 2, 3, 15 and 16Population: The full analysis set included all participants who had received at least one dose of LTT462.
Assessment of Pharmacodynamic (PD) effects of LTT462 in tumor, pre- and post- treatment tumor biopsies were examined for expression of DUSP6. For assessment of PD effects in blood, levels of DUSP6 were measured in blood samples.
Outcome measures
| Measure |
LTT462 45 mg QD
n=2 Participants
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 Participants
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 Participants
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 Participants
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 Participants
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 Participants
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 Participants
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 Participants
Participants received 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 Participants
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 Participants
Participants received 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Changes From Baseline in Relative Quantity (RQ) of Dual Specificity Phosphatase 6 (DUSP6) in Tumor Tissue and in Blood
Tumor Sample
|
-0.2 Ratio
Standard Deviation NA
Standard deviation was not calculated due to single participant in the arm.
|
0.8 Ratio
Standard Deviation 1.11
|
-1.1 Ratio
Standard Deviation 29.46
|
-28.8 Ratio
Standard Deviation NA
Standard deviation was not calculated due to single participant in the arm.
|
-31.0 Ratio
Standard Deviation 31.06
|
-56.5 Ratio
Standard Deviation NA
Standard deviation was not calculated due to single participant in the arm.
|
-22.2 Ratio
Standard Deviation 28.67
|
-79.9 Ratio
Standard Deviation NA
Standard deviation was not calculated due to single participant in the arm.
|
-61.8 Ratio
Standard Deviation 4.16
|
-14.4 Ratio
Standard Deviation 22.27
|
|
Changes From Baseline in Relative Quantity (RQ) of Dual Specificity Phosphatase 6 (DUSP6) in Tumor Tissue and in Blood
Blood Sample
|
-50.8 Ratio
Standard Deviation 6.14
|
-66.1 Ratio
Standard Deviation 40.22
|
-35.2 Ratio
Standard Deviation 27.33
|
-34.7 Ratio
Standard Deviation 22.02
|
-42.5 Ratio
Standard Deviation 16.56
|
-43.0 Ratio
Standard Deviation 13.67
|
-40.1 Ratio
Standard Deviation 9.92
|
-40.4 Ratio
Standard Deviation 21.04
|
-39.2 Ratio
Standard Deviation 12.98
|
-32.9 Ratio
Standard Deviation 18.71
|
Adverse Events
LTT462 45 mg QD
Serious events: 1 serious events
Other events: 2 other events
Deaths: 1 deaths
LTT462 100 mg QD
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LTT462 150 mg QD
Serious events: 3 serious events
Other events: 6 other events
Deaths: 0 deaths
LTT462 200 mg QD
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
LTT462 300 mg QD
Serious events: 5 serious events
Other events: 8 other events
Deaths: 2 deaths
LTT462 400 mg QD
Serious events: 1 serious events
Other events: 6 other events
Deaths: 1 deaths
LTT462 450 mg QD
Serious events: 8 serious events
Other events: 12 other events
Deaths: 1 deaths
LTT462 600 mg QD
Serious events: 4 serious events
Other events: 5 other events
Deaths: 1 deaths
All QD Participants
Serious events: 23 serious events
Other events: 46 other events
Deaths: 6 deaths
LTT462 150 mg BID
Serious events: 3 serious events
Other events: 6 other events
Deaths: 1 deaths
LTT462 200 mg BID
Serious events: 5 serious events
Other events: 12 other events
Deaths: 0 deaths
All BID Participants
Serious events: 8 serious events
Other events: 18 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
LTT462 45 mg QD
n=2 participants at risk
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 participants at risk
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 participants at risk
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 participants at risk
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 participants at risk
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 participants at risk
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 participants at risk
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 participants at risk
Participants received 450 mg LTT462 QD as oral capsules.
|
All QD Participants
n=47 participants at risk
Participants received 45 to 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 participants at risk
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 participants at risk
Participants received 200 mg LTT462 BID as oral capsules.
|
All BID Participants
n=18 participants at risk
Participants received 150 and 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Retinopathy
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
10.6%
5/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Fatigue
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Gait disturbance
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
General physical health deterioration
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Swelling
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Biliary tract infection
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Peritonitis bacterial
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Sepsis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Glomerulonephritis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Renal injury
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Hypotension
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
Other adverse events
| Measure |
LTT462 45 mg QD
n=2 participants at risk
Participants received 45 mg LTT462 QD as oral capsules.
|
LTT462 100 mg QD
n=3 participants at risk
Participants received 100 mg LTT462 QD as oral capsules.
|
LTT462 150 mg QD
n=6 participants at risk
Participants received 150 mg LTT462 QD as oral capsules.
|
LTT462 200 mg QD
n=4 participants at risk
Participants received 200 mg LTT462 QD as oral capsules.
|
LTT462 300 mg QD
n=8 participants at risk
Participants received 300 mg LTT462 QD as oral capsules.
|
LTT462 400 mg QD
n=6 participants at risk
Participants received 400 mg LTT462 QD as oral capsules.
|
LTT462 450 mg QD
n=12 participants at risk
Participants received 450 mg LTT462 QD as oral capsules.
|
LTT462 600 mg QD
n=6 participants at risk
Participants received 450 mg LTT462 QD as oral capsules.
|
All QD Participants
n=47 participants at risk
Participants received 45 to 600 mg LTT462 QD as oral capsules.
|
LTT462 150 mg BID
n=6 participants at risk
Participants received 150 mg LTT462 BID as oral capsules.
|
LTT462 200 mg BID
n=12 participants at risk
Participants received 200 mg LTT462 BID as oral capsules.
|
All BID Participants
n=18 participants at risk
Participants received 150 and 200 mg LTT462 BID as oral capsules.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
4/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
4/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
66.7%
4/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
40.4%
19/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
4/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
38.9%
7/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Asthenia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
10.6%
5/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Cystoid macular oedema
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Device related infection
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Furuncle
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Influenza
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Rash pustular
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Skin infection
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Injury, poisoning and procedural complications
Procedural dizziness
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Injury, poisoning and procedural complications
Urostomy complication
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Alanine aminotransferase increased
|
100.0%
2/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
19.1%
9/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Ammonia increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Amylase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
3/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Aspartate aminotransferase increased
|
100.0%
2/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
21.3%
10/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
27.8%
5/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
100.0%
3/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
14.9%
7/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood creatine phosphokinase increased
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
4/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
14.9%
7/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
3/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
19.1%
9/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood potassium increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood triglycerides increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Blood urea increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
C-reactive protein increased
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Eosinophil count increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Gamma-glutamyltransferase
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
14.9%
7/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Granulocyte count increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Lipase
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Lipase increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Liver function test
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Platelet count decreased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
Troponin increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Investigations
White blood cell count increased
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
29.8%
14/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
3/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperalbuminaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperamylasaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperlipasaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
17.0%
8/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
10.6%
5/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
22.2%
4/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Muscle tightness
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour associated fever
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.8%
6/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Headache
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Hypotonia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Seizure
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Syncope
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Nervous system disorders
Visual field defect
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Psychiatric disorders
Anxiety
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Psychiatric disorders
Depression
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Nephritis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Reproductive system and breast disorders
Genital haemorrhage
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Reproductive system and breast disorders
Metrorrhagia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Reproductive system and breast disorders
Prostatic calcification
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary arterial hypertension
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Agranulocytosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
66.7%
2/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
4/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
38.3%
18/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
22.2%
4/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Cardiac disorders
Cyanosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Endocrine disorders
Goitre
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Cataract
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Chorioretinopathy
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
14.9%
7/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Corneal disorder
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Detachment of retinal pigment epithelium
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Eye pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Macular detachment
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Macular oedema
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Retinal detachment
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
3/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Retinal pigment epitheliopathy
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Retinopathy
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
3/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Vision blurred
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Eye disorders
Visual impairment
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.8%
6/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.8%
6/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
100.0%
3/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
4/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
66.7%
4/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
41.7%
5/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
46.8%
22/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
41.7%
5/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
6/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Faeces soft
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Gingival pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Nausea
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
100.0%
3/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
4/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
66.7%
4/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
44.7%
21/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
3/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
4/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
38.9%
7/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Odynophagia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Face oedema
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Fatigue
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
17.0%
8/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
4/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
6/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
General physical health deterioration
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Malaise
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Mucosal dryness
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Mucosal haemorrhage
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Non-cardiac chest pain
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Oedema peripheral
|
50.0%
1/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.5%
1/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
12.8%
6/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Pain
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Swelling
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Peripheral swelling
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
General disorders
Pyrexia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Hepatobiliary disorders
Hepatosplenomegaly
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Hepatobiliary disorders
Pneumobilia
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Infections and infestations
Cystitis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Dermatitis exfoliative generalised
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
5.6%
1/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
17.0%
8/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
22.2%
4/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Purpura
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
50.0%
2/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
37.5%
3/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
2/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
41.7%
5/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
29.8%
14/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
66.7%
4/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
3/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
38.9%
7/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
2/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
6.4%
3/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
2/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
11.1%
2/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.3%
1/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
33.3%
1/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Hypertension
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
25.0%
1/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
8.5%
4/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Hypotension
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
4.3%
2/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Pelvic venous thrombosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
|
Vascular disorders
Venous thrombosis limb
|
0.00%
0/2 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/3 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/4 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/8 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
16.7%
1/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
2.1%
1/47 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/6 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/12 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
0.00%
0/18 • Adverse events were evaluated from screening until at least 30 days after the discontinuation of study treatment (Up to 2.8 years)
The Safety Set included all participants who had received at least one dose of LTT462.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER